A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis
A Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of IBI112 in Patients With Moderate to Severe Active Ulcerative Colitis
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Listed as NCT05377580, this PHASE2 trial focuses on Ulcerative Colitis (UC) and remains completed. Sponsored by Innovent Biologics (Suzhou) Co. Ltd., it has been updated 7 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Dec 2025 — Present [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Sep 2024 — Dec 2025 [monthly]
Active Not Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Dec 2023 — Jul 2024 [monthly]
Recruiting PHASE2
▶ Show 2 earlier versions
-
Sep 2022 — Dec 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2022 — Sep 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Innovent Biologics (Suzhou) Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .